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Gaucher disease is a recessively inherited lysosomal storage disorder that is caused by a deficiency in 
glucocerebrosidase activity. The clinical expression is markedly heterogeneous with respect to age of 
onset, progression, severity, and neurological involvement. The relative incidence of glucocerebrosidase 
(GC) mutations has been studied extensively for Jewish but not for non-Jewish Caucasian patient 
populations. The present survey on mutant GC genotypes prevalent in Gaucher disease in The Nether­
lands was taken of 72 patients from different genetic backgrounds* This number is more than half the 
total number of affected Gaucher patients to be expected on the basis of the incidence of the disorder in 
this country. Analysis of nine GC mutations led to the identification of 74% of the mutant GC alleles in 
patients from 44 unrelated Dutch families (i.e., families that have lived in The Netherlands for at least 
several generations) and of 44% of the mutant GC alleles in patients from nine unrelated families that 
recently immigrated from both European and non-European countries. The N370S (cDNA 1226G) 
GC mutation proved to occur most frequently (41%) in the unrelated Dutch patients and less fre­
quently (6%) in the unrelated immigrant patients and was always associated with the nonneuronopathic 
(Type 1) form of the disease. Apart from the association of the N370S mutation with Type 1 Gaucher 
disease, the prognostic value of GC genotyping was limited, since a particular GC genotype did not 
correlate closely to a specific clinical course, or to a specific relative responsiveness to enzyme-supple­
mentation therapy. Hum M utat 10:348-358, 1997. © 1997 Wiley-Liss, Inc.
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INTRODUCTION: ANALYSING MUTATIONS 
IN GAUCHER PATIENTS
Gaucher disease is one of the most frequent lyso­
somal storage disorders in humans. The disease is due 
to an autosomal recessively inherited deficiency in 
lysosomal glucocerebrosidase activity (E.C. 3.2.1.45), 
resulting in accumulation of its substrate gluco- 
cerebroside (also named glucosylceramide) in ma­
crophages (Beutler and Grabowski, 1995). Three 
phenotypes are distinguished on the basis of onset of 
neurological symptoms: Type 1, the “adult,” or 
nonneuronopathic, form, Type 2, the “infantile,” or 
acute neuronopathic, form, and Type 3, the “juve­
nile,” or subacute neuronopathic, form. Type 1
Gaucher disease is the most prevalent phenotype that 
varies considerably in age of onset, progression, and 
severity of clinical manifestation. Common features 
are hepatosplenomegaly, anemia, thrombocytopenia, 
and skeletal deterioration (Barranger and Ginns,
1989; Beutler and Grabowski, 1995).
The defective glucocerebrosidase (GC) gene is 
located at chromosome lq21 (Barneveld et al, 1983;
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Ginns et al., 1985). A 95% homologous pseudogene is
located at the same locus on chromosome 1 (Horowitz 
et al., 1989). Cloning of the GC gene has allowed the 
identification of the precise nature of mutations un­
derlying the enzyme deficiency in patients with Gaucher 
disease. More than 50 GC mutations have been re­
ported (for recent reviews on this topic, see Beutler et
al., 1994, 1995; Horowitz and Zimran, 1994). How­
ever, it should be realised that for some of the abnor­
malities in the GC gene, it has not been experimentally 
proven that they are not polymorphisms, but actually 
lead to a deficiency of glucocerebrosidase.
In some populations a relatively small number of 
GC mutations accounts for the majority of the de­
fects in GC alleles of Gaucher patients. In Jewish and 
non-Jewish Caucasian populations, the N370S 
(cDNA 1226G) GC mutation is the most prevalent 
(Amaral et ah, 1993; Horowitz and Zimran, 1994; 
Lacerda et al., 1994a), causing synthesis of a cata- 
lytically abnormal enzyme (Grace et al, 1990; Ohashi 
et al., 1991; van Weely et al., 1993). This mutation 
has so far not been encountered in the Japanese popu­
lation (Ida et alM 1995). The L444P (cDNA 1448C)
GC mutation is relatively frequent in the Jewish and 
non-Jewish Caucasian populations and in Japanese 
populations (Horowitz and Zimran, 1994; Ida et al., 
1995) and leads to synthesis of glucocerebrosidase, 
which is rapidly degraded (Grace et al., 1991; Ohashi
et al, 1991; Grace et al., 1994). Another frequent
GC mutation in Ashkenazi Jewish populations is the 
so-called 84GG insertion (cDNA 84GG), resulting
in synthesis of a truncated enzyme due to the gen­
eration of a frame shift (Beutler et al, 1991). This 
mutation has not been found in the non-Jewish Cau­
casian or Japanese populations (Amaral et al., 1994; 
Horowitz and Zimran, 1994; Ida et al., 1995).
Over the last few years much attention has been 
given to the analysis of GC mutations in Gaucher 
patients for a variety of reasons. First, accurate iden­
tification of Gaucher disease carriers is not feasible 
on the basis of residual enzyme activity in extracts of 
blood cells or cultured fibroblasts (Daniels and Glew, 
1982; Wenger and Roth, 1982). In principle, geno-
typing should allow reliable identification of carriers 
of (known) mutant GC alleles, and knowledge about 
the relative frequencies of GC mutations in Gaucher 
patients should facilitate genetic counseling.
Second, it has been attempted to establish a cor­
relation between GC genotype and severity of 
Gaucher disease manifestation (see, e.g., Beutler, 
1993). Unfortunately, researchers disagree about the 
prognostic value of GC genotyping for clinical ex­
pression of the disorder (see, e.g., Sibille et al, 1993; 
Sidransky and Ginns, 1994)- Although the experi­
ence of most investigators concerning the results of 
genotyping may not in fact be that different, some 
prefer to stress the actual clinical variability within 
each GC genotype, whereas others prefer a statisti­
cal evaluation of the genotype results. However, con­
sensus does exist about the important fact that 
hetero-alfelic or homo-allelic presence of the N370S 
GC mutation is not associated with a neuronopathic 
course of the disease (with the exception of one child)
(McCabe et ah, 1996).
Third, it has been suggested that GC genotypes of 
Gaucher patients could be predictive for their re­
sponse to enzyme-supplementation therapy and, 
moreover, would allow recommendations to be made 
for the type of dosing regimen to be used. However, 
so far, GC genotyping has not rendered such guide­
lines (Zimran et al., 1994).
Some literature data on GC genotypes of Gaucher 
patients should be carefully interpreted. In general, 
proportionally more material from severe Gaucher 
disease cases (neuronopathic phenotypes, or severe 
nonneuronopathic phenotypes) has been available for 
mutation analysis. Thus it cannot be excluded that 
particular mutations have been over-represented. 
Furthermore, the most impressive data with respect 
to GC genotypes of Gaucher patients particularly 
concern Jewish populations, in which Type 1 Gaucher 
disease occurs relatively frequently (Barranger and
Ginns, 1989, Beutler and Grabowski, 1995).
As in many other countries, Gaucher disease is a 
rare disorder in The Netherlands. Nevertheless, cli­
nicians and fundamental researchers have long been 
interested in it so that a relatively accurate estima­
tion can be made for the local incidence of the clini­
cally manifest disorder, being 100—150 patients in the 
total population of 15,000,000. Both the existence of a 
national patient society and the collaboration between 
various clinical genetic centers involved in the bio­
chemical diagnosis of Gaucher disease allowed us to 
determine GC genotypes for a high percentage (50- 
70%) of all Gaucher patients in The Netherlands.
Here, we document the frequency of various GC 
mutations in families with incidence of Gaucher dis­
ease that have lived in The Netherlands for several 
generations and in families that have recently immi­
grated to The Netherlands. We discuss the prognos­
tic value of the GC genotypes with respect to the 
phenotypic manifestation and to the response to en­
zyme-supplementation therapy.
MATERIALS AND METHODS 
Gaucher Patients
A diagnosis of Gaucher disease was made in 72 
patients from 53 families living in The Netherlands.
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The presence of Gaucher disease was either assumed 
on the basis of characteristic clinical symptoms and/ 
or the presence of Gaucher cells in bone marrow or 
liver biopsies, or was investigated because of an af- 
fected sibling. The clinical diagnosis was biochemi­
cally confirmed by the demonstration of a markedly 
reduced glucocerebrosidase activity in leukocytes 
and/or urine samples and/or cultured skin fibroblasts
(Daniels and Glew, 1982; Aerts et al, 1991).
Patients were classified as Type 1, 2, or 3 accord­
ing to the criteria described by Barranger and Ginns 
(1989). Two patients showed an unusual manifesta­
tion of the disease. Patient No. 56 (see Table 2) de­
veloped characteristic clinical signs of Gaucher 
disease at a very young age. At the juvenile age, he 
started to suffer from neurological symptoms that 
were not identified as signs characteristic for Type 3 
Gaucher disease. He died at the age of 21 years due 
to severe pulmonary involvement. Patient No. 57 so 
far developed no visceral manifestations of Gaucher 
disease. At the age of 42, neurological abnormalities 
resembling Parkinsonian disease developed. Although 
the glucocerebrosidase activities in blood cells and 
cultured skin fibroblasts of this patient were mark­
edly reduced, it cannot be excluded that the clinical 
complications have an unrelated cause.
Only a few of the examined patients were known 
to have Ashkenazi Jewish ancestry. Such an ethnic 
background can, however, not be excluded with cer­
tainty since there have been various episodes of Jew­
ish immigration in the Low Countries. In our study 
we distinguish families that have lived in The Neth­
erlands for several generations (so-called native fami­
lies) and families that have recently emigrated from 
European and non-European countries to The Neth­
erlands (so-called immigrant patients).
We have also analysed the GC genotype in samples 
from several unrelated Type 1 Gaucher patients that 
had been sent to us by other laboratories in Europe. 
These samples came from Czech Republic (n=4), 
France (n=5), Germany (n=20), Belgium (n=l), 
and Portugal (n = l) .
Analysis of GC Mutations
Genomic DN A was isolated from leukocytes and/ 
or cultured skin fibroblasts. The analyses of nine GC 
mutations were performed by restriction-enzyme di­
gestions upon polymerase chain reaction (PCR) am­
plification of genomic DNA (for details, see Table 
1). The primers were manufactured by Pharmacia 
(Uppsala, Sweden) and chosen in such a way that 
the pseudogene was not amplified. Restriction-en- 
zymes BsaBI, HphI, Styl, Neil, and BanI were from 
New England Biolabs (Beverly, MA) and Xhol, MspI,
and HincII from Pharmacia. The restriction-enzyme
reactions were performed according to the instruc­
tions of the manufacturers. The resulting fragments 
were analysed on polyacrylamide gels or agarose gels 
as described by Sambrook et al. (1989).
The mutations resulting in the amino acid substi­
tutions N370S and V394L (cDNA 1297T) were
analysed using mismatch PCR, as described by Beutler
et al. (1990) for the N370S mutation and by Beutler 
et al. (1993a) for the V394L mutation, with modifi­
cations in the primers used. Also, the insertion mu­
tation 84GG was analysed using mismatch PCR, as 
described by Beutler et al. (1991).
The L444R D409H, (cDNA 1342C), and R463C
(cDNA 1504T) mutations were analysed using the 
same upstream and downstream primers (see Table 
1), The products were digested with different restric­
tion enzymes.
We did not investigate the presence of the
R456G (cDNA 1483C) and V460V (cDNA
1497C) mutations, which are present in the com­
plex alleles RecNcil and RecTL due to recombi­
nations with the pseudogene (for a review see
Horowitz and Zimran, 1994). Thus we cannot ex­
clude that in some cases the L444P mutation was 
in fact a RecNcil mutation.
Southern Blot Analysis
Genomic DNA was isolated and digested with 
restriction enzyme SspI (New England Biolabs) ac­
cording to a previously described procedure (Zimran 
et al., 1990). After separation of the fragments on a 
0.5% agarose gel and transfer to Hybond (Amersham, 
Buckinghamshire, UK), hybridisation was performed 
with radioactively labelled full-length gluco­
cerebrosidase cDNA.
RESULTS
Incidence of Glucocerebrosidase Genotypes of 
Gaucher patients
We analysed nine GC mutations, i.e., the N370S,
L444F¡ 84GG, IVS24-1 (genomic DNA 1067A), 
V394L, D409H, R463C, R496H (cDNA 1604A), and 
a 55-bp deletion at cDNA position 1263-1317, in 72
Gaucher patients who live or have lived in The Neth­
erlands. An overview of the GC genotypes of the pa­
tients is presented in Table 2, including their country 
of origin. The relative incidence of GC mutations in 
unrelated Gaucher patients is shown in Figure 1.
The most common mutation in the so-called na­
tive Type 1 Gaucher patients, whose families have 
lived in The Netherlands for several generations,
proved to be the N370S GC mutation. In fact, > 
90% of these patients carried the N370S GC muta-
TABLE l. Analysis of Nine GC Mutations in Gaucher Patients Living in The Netherlands9
Mutation Genomic Genomic
Restriction
enzyme
used
Control
fragments
<bp)b
Mutant
fragments
<bp)b
Reference of
Name cDNA Sequence upstream primer sequence Sequence downstream primer sequence primers used
N370S 1226G 5 ' CTTTGCCTTTGTCCTTACCCTcGA 3 ' 5817-5840 5 ' GTTACGCACCCAATTGGGTCCTCC 3' 5897-5920 Xhol 104 84, 20 Beutier et al., 
this study
1990;
V394L 1297T 5' GGACCGACTGGAACCTTGCCC 3 ' 5865-5885 5 ' G ACT GTCG AC AAAGTTAgGC 3 ' 5914-5933 Ban! 47, 22 69 Beutler et al., 1993a
D409H 1342C 5' GGAGGACCCAATTGGGTGCGTAAC 3' 5897-5920 5 ' G AGG CACATCCTTAG AG GAG CTAGG G 3' 6579-6604 StyS 396 ,156  
63, 56, 37
396, 153, 
93, 63
This study
L444P 1448C 5 ' GGAGGACCCAATTGGGTGCGTAAC 3' 5897-5920 5 '  GAGGCACATCCTTAGAGGAGCTAGGG 3' 6579-6604 Neil 708 536 ,172 This study
R463C 1504T 5 ' GGAGGACCCAATTGGGTGCGTAAC 3' 5897-5920 5 ' GAGGCACATCCTTAGAGGAGCTAGGG 3 ' 6579-6604 Mspl 592, 116 708 This study
R496H 1604A 5' GCTCTGCTGTTGTGGTCGTG 3' 6463-6482 5 ' GCCCAGTGCCTCCTTGAGTA 3 ' 6700-6719 Hphl 124, 81,
40, 12
124, 46,
40, 35, 12
Beutler et al., 1993b
84GG 84GG 5' GAATGTCCCAAGCCTTTGA 3 ' 979-997 5' CACTG CCTGAAGTAGAtGC 3' 1035-1053 BsaBl 75 57, 18 Beutler et al., 1991
1VS2+1 --- 5" GAATGTCCCAAGCCTTTGA 3 ' 979-997 5' AG CT GAAG CAAG AGAATCG 3 ' 1317-1335 Hphl 141,116  
100 
750, 678
241, 116 This study
55del 1263-1317del 5 ' TGTGTGCAAG GTCCAG GATCAGTTG C 3 ' 5177-5202 5' GAGGCACATCCTTAGAGGAGCTAGGG 3 ' 6579-6604 Hindi 1373 This study
“Genomic DNA was amplified using the PCR technique and products were digested with several restriction enzymes as indicated. Numbering of sequences of the primers corresponds to the genomic sequence numbering 
according to Horowitz et al. (1989). Sequences were derived from Horowitz et al. (1989) with corrections described by Beutler et al. {1992). Mismatch nucleotides are given in lower case.
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ta b le  2. GC Genotypes of Individual Patients Living in The N etherlands3
A. Native G aucher patients of families living in The 
N etherlands for several generations
Patient Family
no. no. Genotype
Type 1 patients
1 1 N370S/?
2 2 N370S/L444P
3 3 N370S/IVS2 + 1
4 4 N370S/84GG
5 5 N370S/L444P
6 5 N370S/L444P
7 5 N370S/L444P
8 5 N370S/L444P
9 5 N370S/L444P
10 6 N370S/?
11 6 N370S/?
12 6 N370S/?
13 7 N 370S/N 370S
14 7 N 370S/N 370S
15 8 N370S/L444P
16 9 N370S/L444P
17 10 N370S/IVS2 + 1
18 10 N370S/IVS2-f 1
19 11 N370S/?
20 12 N370S/?
21 13 N370S/L444P
22 14 N370S/?
23 14 N370S/?
24 15 N370S/L444P
25 15 N370S/L444P
26 15 N370S/L444P
27 16 N370S/?
28 17 N370S/?
29 18 N370S/?
30 19 N370S/?
31 20 ?/?
32 21 N370S/84GG
33 22 N370S/?
34 23 N370S/L444P
35 23 N370S/L444P
36 23 N370S/L444P
37 24 ?/?
38 25 ?/?
39 26 N370S/L444P
40 27 N370S/L444P
41 27 N370S/L444P
42 28 N370S/?
43 29 N370S/?
44 30 N370S/L444P
45 31 N370S/L444P
46 32 N370S/?
47 33 N370S/L444P
48 33 N370S/L444P
49 34 N370S/L444P
50 35 N370S/L444P
51 36 N370S/?
52 37 N370S/L444P
53 38 N370S/L444P
54 38 N370S/L444P
55 38 N370S/L444P
Adult patients with un usual clinical presentation
56 39 L444P/L444P
57 40 ?/?
Type 2 and 3 patients
58 41 L444P/L444P
59 41 L444P/L444P
60 42 L444P/L444P
61 43 L444P/L444PI
62 44 L444P/?
B. Gaucher patients of families recently immigrated to 
The Netherlands_________________________________ __
Patient Family Country 
no.______________ n o _____ Genotype________ ancestry
Type 1 patients
63 45 R463C/? Surinam
64 46 R463C/? Great Britain
65 47 N370S/? Former
Yugoslavia
66 48 ?/? Morocco
67 48 ?/? Morocco
Type 2 and 3 patients
68 49 L444P/L444P Antilles
69 50 L444P/L444P Morocco
70 51 L444P/? Poland
71 52 ?/? Poland
72 53 ?/? Turkey
°Genomic DNA from leukocytes or cultured fibroblasts was iso­
lated and the presence of nine GC mutations was analysed using 
restriction enzyme analyses of PCR products as described in Ma­
terials and Methods. The mutations analysed were the N370S 
(cDNA 1226G), L444P (cDNA 1448C), 84GG (cDNA 84GG), 
1VS2+1 (genomic DNA 1067A), V394L (cDNA 1297T), D409H 
(cDNA 1342C), R463C {cDNA 1504T), R496H (cDNA 1604A), 
and a 55 bp deletion at cDNA position 1263-1317. In some cases, 
the L444P mutation might be a RecNcil mutation (see Materials 
and Methods). Patients No. 62 and Nos. 70-72 were diagnosed 
as presumably Type 2 Gaucher patients; patients Nos. 58-61, 
68, and 69 as presumably Type 3 Gaucher patients. 
bPatient identified on the basis of DNA analysis of parents and 
relatives.
?Mutation unknown (no. N370S, L444P, 84GG, IVS2 + 1, V394L, 
D409H, R463C, R496H, or a 55-bp deletion at cDNA-position 
1263-1317).
tion at least in the hetero-allelic form (Table 2A). 
The second most common mutation in these patients 
was the L444P GC mutation, which occurred, how­
ever, only in the hetero-allelic form, except for one 
case (Patient No. 56). All the other mutations tested 
were not or were rarely detected in these patients. 
The two unrelated Type 1 patients showing the 84GG 
insertion (Patients No. 4, No. 32) had Ashkenazi 
Jewish ancestors, substantiating the claim that this
mutation is exclusively found within this ethnic group
(Beutler et al, 1991),
In the neuronopathic Type 2 as well as Type 3 
Gaucher patients, homozygosity for the L444P mu­
tation is commonly encountered, and this was also 
the case for the native Types 2 and 3 Gaucher pa­
tients. None of the investigated neuronopathic pa­
tients carried the N370S GC mutation.
The analysis of four GC mutations (N370S,
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FIGURE 1. Relative frequencies of GC mutations in unrelated 
Gaucher patients in The Netherlands. A. Native Gaucher 
patients; B. native Type 1 Gaucher patients; C. native Types 
2 and 3 Gaucher patients; D. immigrant Gaucher patients. 
The isolation of genomic DNA and analyses of nine muta­
tions are described in the legend to Table 1.
L444R 84GG, and IV S2+1) led to the identifica­
tion of 79% of the mutant GC alleles of all native 
Dutch Gaucher patients.
The relative incidence of GC mutations in the 
investigated Gaucher patients who had recently im­
migrated from both European and non-European 
countries was different (Table 2B). Most importantly, 
the N370S GC mutation occurred less frequently, 
i.e., in 20% of the immigrant Type 1 Gaucher pa- 
tients (cf. Fig. ID). However, the small number of 
immigrant Gaucher patients, their diverse ethnic 
background, and the fact that in some cases the par­
ents were consanguineous do not allow a statement 
about the statistical significance of the difference in 
frequency of mutant alleles among native and immi­
grant Gaucher patients.
In Table 3, a comparison is made of the inci­
dence of the GC genotypes of native Type 1 
Gaucher patients in The Netherlands with those 
of patients in other populations. It can be con­
cluded that the present findings for the Dutch 
Type 1 Gaucher patients resemble those reported 
for patients living in other European countries (in­
cluding Type 1 Gaucher patients in France) 
(Caillaud et al., 1995), as well as our own data for 
34 patients living in other European countries. 
Furthermore, Table 3 shows that among Jewish 
Type 1 Gaucher patients, the N370S GC muta­
tion is particularly prevalent: > 65% of the GC 
alleles carried a N370S mutation. It was initially 
reported that among non-Jewish Gaucher patients,
the N370S GC mutation is far less prevalent, con­
stituting only 23% of the total m utant GC alleles 
(Horowitz et al., 1993). However, more recent data 
indicate that the difference in frequency of this 
mutation among Jewish and non-Jewish Cauca­
sian Type 1 Gaucher patients is less spectacular. 
Among the Type 1 Gaucher patients in the Euro­
pean countries (summarised in Table 3), the 
N370S mutation was present in 47% of the m u­
tated GC alleles.
Value of GC Genotype With R espect to 
Manifestation of Gaucher D isease  
Correlation between GC genotype and severity 
of Type 1 Gaucher disease
A score taking into account the severity of a 
variety of clinical symptoms is commonly used to 
assess the severity of disease m anifestation in 
Gaucher patients (Zimran et aL, 1992). The se­
verity scoring index (SSI) was calculated for 41 
Type 1 Gaucher patients. No significant differ­
ences in disease severity were noted between male 
and female Gaucher patients with similar geno­
types. It can be seen in Figure 2 that the SSI did 
not correlate with specific GC genotypes. M ore­
over, differences in SSI were observed between 
siblings carrying the same GC mutations. Patients
5—9 from family 5 (Table 2A), e.g., had an SSI of 
7* 5, 12, 5, and 8, respectively, and patients 24- 
26 from family 15 showed an SSI of 16, 5, and 3,
respectively. W hen GC genotypes of patients were 
related to individual parameters of disease expres­
sion, such as splenomegaly, hepatomegaly, hema­
tological symptoms, or bone de terio ra tion , a 
comparable variability was noted (not shown).
In our experience, homozygosity for the L444P GC
mutation was not always absolutely linked to a spe­
cific clinical course. Patient No. 56 (cf. Table 2A), 
who developed lethal pulmonary complications due 
to excessive infiltration of the lungs by storage cells,
was found to be homozygous for the L444P GC mu­
tation. At the age of death (21 years), no neurologi­
cal abnormalities characteristic for Type 3 Gaucher 
disease had yet developed. Table 3 shows that this 
mutant genotype was present in several Type 1 
Gaucher patients from European and non-European 
countries.
Patient No. 57 (cf. Table 2A) showed an un­
usual clinical presentation of Gaucher disease. He 
developed Parkinson-like neurological symptoms 
and no visceral Gaucher disease symptoms. The 
genotype of this patient is still under investiga­
tion, since he carried none of the nine GC m uta­
tions tested for.
TABLE 3. Comparison of Incidence of GC Genotypes of Native Dutch Type 1 Gaucher Patients With Literature Data
No. of _______________________________________________________ GenotÿPgX  1 V  » V  1
unrelated N370S/ N370S/ N370S/« N370S/ N370S/ N370S/ N370S/ L444P/ L444P/ L444P/ D409H/ ?/
Origin patients2 N370S L444P complex 84GG IVS2+1 R463C 9A L444P D409H 7m ?* 7m References0
The Netherlands 40 1 16 2 2 0 14 1 0 0 0 4 This study
Several European 34 5 7 1 2 1 11 1 1 1 1 2 This study
countries1*
Spain 26 6 10 1 0 0 0 8 0 0 0 1 0
e
Portugal 23 5 4 2 1 2 6 0 1 2 f.g■
Italy 48 6 15 3 0 14 1 0 4 3
h,i
Greece 6 0 3 0 0 1 2 0 0 0 0 0 j
Great-Britain 21 1 6 0 0 0 6 1 0 4
k.I
Europe 198 24 61 6 3 5 4 61 4 1 6 2 15
Non-Jewish 102 10 22 9 0 0 1 25 7 0 4 0 4 m,n,o
(USA and Israel) * * 4
Jewish 545 245 48 10 118 17T 0 41T 0 0 0 0 2 ’
m-p
(USA and Israel)
Austral(as)ian 18 2 2 1 2 0 5 3 1 1 q.r
Japan 20 0 0 0 0 0 0 6 0 4 0 6
s
aNot indicated for the non-Jewish patients noted in Refs, i, 1, m, o. 
bRecNciI or RecTL mutation.
cIn this overview, the genotypes of 40 unrelated Dutch Gaucher patients and 34 Gaucher patients from other European countries are indicated. In all studies, the N370S and L444P mutations were 
analysed. The other mutations analysed were: This study: D409H, R463C, V394L, 84GG, 1VS2-4-1, R496H, 55bp deletion; (e) Cormand et aL, (1995): D409H, R463C, 84GG, IVS2+1, RecTL and 
RecNcil; (f) Amaral et al. (1994): 17 mutations; (g) Sa Miranda et al. (1995): exons 5, 9, 10, R463C, IVS2+1, RecNcil, P415R, R120Q; (h) Tuteja et aï. (1993): exons 9 and 10; (i) Filocamo et 
al. (1995): exons 8-11; (j) Michelakakis et al. (1995): D409H, R463C, 84GG, IVS2+1, R496H, 55bp deletion; (k) Mistry et al. (1992): R463C, 84GG, P415R, R120Q; (I) Walley et ai. (1993): 
R463C, 84GG, IVS2+1; (m) He and Grabowski (1992): 84GG, IVS2+1; (n) Horowitz et al. (1993): D409H, R463C, R496H, 84GG, JVS2+1, RecTL and RecNcil; (o) Beutler and Gelbart (1993): 
27 mutations; (p) Sibille et aL (1993): 84GG, IVS2+1; (q) Lewis et al. (1994): R463C, 84GG; (r) Nelson et aL (1995): RecNcil and RecTL; (s) Ida et al. (1995): D409H, R463C, 84GG, IVS2+1, 
F213I. Several rare GC genotypes comprising one or a few Type 1 Gaucher patients are not included here; see Refs, i, k-o, q, s, and this study (R463C/?, Table 2B). 
dCzech Republic (n=4), France (n=5), Germany (n=20), Belgium (n=l), Turkey (n=l), Portugal (n=l), Great Britain (n=l) and former Yugoslavia (n=l).
The minimal number of patients with the particular genotype is indicated (in Ref. p, it was noted that 48 patients had genotype N370S/IVS2 + 1, N370S/? or ?/?).
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FIGURE 2. Correlation between GC  genotypes of 41 Type 1 
Gaucher patients in The Netherlands and the severity scor­
ing index. The isolation of genomic DN A  and analyses of 
nine mutations are described in the legend to Table 1. The 
severity scoring index (SSI) was determined using the crite­
ria described by Zimran et al. (1992).
Asymptomatic individuals
During our studies we noted in at least three un­
related families the occurrence of individuals with 
low glucocerebrosidase activities compared with those 
in control subjects having no clear clinical symptoms 
related to Gaucher disease, despite the fact that they 
were older than 65 years. An example is presented in 
Figure 3, showing the GC genotypes of members of a 
family (family 5 in Table 2) with Type 1 Gaucher dis­
ease. In the second generation, five out of nine sib­
lings were heterogeneously affected patients. AH five 
patients were compounds for the L444P and N370S 
GC mutations. Interestingly, the asymptomatic, 80- 
year-old mother proved to be homozygous for the
N370S mutation.
Prognostic Value of GC Genotypes of Type 1 
Gaucher Patients With Respect to Response to 
Enzyme-supplementation Therapy
In The Netherlands, 34 Type 1 Gaucher patients
are presently treated by enzyme-supplementation
therapy, i.e., chronic intravenous supplementation 
with a modified glucocerebrosidase (alglucerase; 
marketed by Genzyme, Boston, MA as Ceredase). 
All patients participate in a co-ordinated study that 
aims to establish the minimal dose required for a sat­
isfactory clinical response for each individual (Plollak
et al, 1995), Briefly, patients initially rcceive a low 
dose of enzyme (1.15 IU/kg body weight) three times 
a week. On the basis of defined response criteria, 
the dose is adjusted every half year (doubling, 
maintenance, or tapering). As previously described 
(Hollak et ah, 1995), the response to enzyme- 
supplementation therapy is variable among the 
patients. No relationship between the various GC 
genotypes and responsiveness to therapeutic  in­
tervention was noted (data not shown), as also
described by Zimran et ah (1994).
DISCUSSION
The GC genotypes of Gaucher patients in The 
Netherlands have been analysed in this study. Be­
cause of the large number of analysed patients (n=  72 
from 53 unrelated families), the data are probably 
representative for this population.
The data obtained in The Netherlands are con­
sistent with findings (made by several researchers and 
ourselves) for Gaucher patient populations living in 
other countries (Table 3). The most commonly en­
countered mutation is the N370S GC mutation, 
which in the homo - and hetero-allelic form is associ­
ated with a nonneuronopathic clinical course. A n­
other common defect is the L444P GC mutation. A
large proportion of the native Dutch Type 1 Gaucher
patients carries both the N370S and the L444P GC 
mutations. Homozygosity for the L444P GC m u­
tation was noted for Type 2 as well as for Type 3 
Gaucher patients and for one adult patien t with 
an unusual manifestation of Gaucher disease. The 
observed distribution of homozygotes and het- 
erozygotes for the L444P GC m utation is almost 
exactly identical to that predicted by the Hardy- 
Weinberg equilibrium.
II 1 2 3 4 5 6
figure 3. G C  genotypes in a Dutch family with incidence of 
Type 1 Gaucher disease. It was noted that the gluco­
cerebrosidase activity in urine samples and leukocyte extracts 
from the mother (1.1) was not higher than that in the affected
7 8 9 10 11 12 13 14 15
siblings. The SSI of the symptomatic Gaucher patients was 
as follows: 7 (II.2), 8 (II.4), 5 (II.6 ) 12 (II.7), and 5 (11.14). A  
N 370S  mutated allele is indicated in grey, a L444P mutated 
allele in black and a wild-type allele in white.
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The most important conclusion to he drawn from 
our investigation is that the (hetero-allelic) pres­
ence of the N370S GC allele allows prediction of 
a nonneuronopathic clinical course, as proposed 
earlier by McCabe et al. (1996). This conclusion
is particularly relevant for those ethnic groups in 
which the N370S mutation occurs frequently (e.g., 
the Jewish and non-Jewish Caucasian popula­
tions). O ur findings for immigrant Gaucher pa­
tients and those described by Ida et al. (1995) for 
Japanese patients suggest that the significance of 
GC genotyping for genetic counseling may be less 
for other ethnic populations.
Despite the high frequency of the N370S muta­
tion, relatively few homozygotes for this mutation 
were identified among the Gaucher patients investi­
gated by us. The observed distribution of homozy­
gotes and heterozygotes for the N370S mutation 
among native Dutch Gaucher patients, 2% and 77%,
respectively, differs significantly for that predicted by 
the Hardy-Weinberg equilibrium, 17% and 48% re­
spectively. Only the patients in a single Dutch fam­
ily were found to be homozygous for this mutation. 
However, in family studies we detected an 80-year- 
old asymptomatic N370S homozygote. These results 
suggest that the N370S/N370S GC genotype may 
usually result in no (or an extremely mild) manifes­
tation of Gaucher disease. This was also suggested 
after analysis of the N370S GC gene frequency in 
the Portuguese population and in the American 
Ashkenazi Jewish population (Beutler et al., 1993c; 
Lacerda et aL, 1994b). Interestingly, a relatively large
number of symptomatic, although usually mildly af­
fected, N370S homozygotes have been noted in 
Ashkenazi Jewish populations (see Table 3) *
The origin of the N370S GC gene mutation in 
the Dutch population is unclear. As previously noted 
for Portuguese Gaucher patients (Lacerda et al.,
1994a), the N370S GC mutation in Dutch Gaucher
patients is linked to the same P v l.l  haplotype as in 
Ashkenazi Jewish Gaucher patients. This neither 
proves nor excludes the likely possibility that the 
N370S mutation was introduced by Ashkenazi Jew­
ish individuals in The Netherlands.
During our genotype analysis, we observed a pit­
fall in the assignment of homozygosity for the N370S 
mutated GC allele. Using a common procedure for 
the detection of the N370S mutation, we initially 
assigned the N370S/N370S GC genotype to several 
Type 1 Gaucher patients from two unrelated families 
(families 6  and 17 in Table 2). However, we observed 
that one of the parents in each family did not carry a 
N370S mutated GC allele. In the case of one family,
false paternity can be excluded and in the case of the
other family, it is extremely unlikely on the basis of 
the transmission of another inherited abnormality, 
It was examined by us whether an intragenic dele­
tion underlay the problems with PCR-based analysis 
for the N370S mutation. Southern blot analysis of 
genomic DNA digested with the restriction enzyme 
Sspl (Zimran et al., 1990) rendered no indications 
for the presence of a deletion of 100 bp or more. 
Comparison of the ratios of radioactivity of the bands 
for the glucocerebrosidase gene and pseudogene did 
not point to the occurrence of a deletion of the en­
tire coding region of the glucocerebrosidase gene
(Beutler and Gelbart, 1994). We are studying this
further. It is evident that special care should be taken 
to verify apparent homozygosity for a particular mu­
tation as established with PCR techniques. Ideally, 
the genotype of patients should be confirmed by those 
of their parents.
The prognostic value of GC genotypes of Type 1 
Gaucher patients with respect to the severity of the 
manifestation of the disease, or with respect to re­
sponsiveness to enzyme-supplementation therapy 
proved to be limited in our experience. Among pa­
tients with an identical mutant GC genotype, con­
siderable variability existed with respect to severity 
of clinical expression and to responses to therapeu­
tic intervention. This was, in fact, even noted among 
siblings. We feel that the value ofGC mutation analy­
sis in countries such as The Netherlands is, there­
fore, to be found in the exclusion of a neuronopathic 
course of the disease by identification of the pres­
ence of the N370S GC allele, as well as accurate iden­
tification of carriers and presymptomatic patients in 
families with incidence of Gaucher disease.
It will be of interest to determine the N370S gene 
frequency in The Netherlands in order to obtain in­
sight in the incidence of N370S GC homozygosity 
and its association with actual disease manifestation. 
At present, random screening for carriers in The 
Netherlands should not be advocated, since the gen­
eral outcome of homozygosity for the N370S GC 
mutation, theoretically the most frequent mutant 
genotype, is still not known. Consequently, no solid 
basis is present for adequate genetic counseling that 
should be associated with carrier testing in the gen­
eral population.
In conclusion, the results of our investigation in­
dicate once more that other factors besides the na­
ture of m utant glucocerebrosidase in Gaucher 
patients modulate the clinical expression of the dis­
ease (for a more detailed discussion, see Aerts et al.,
1993). Although GC genotyping of Gaucher patients
is re commendable, its prognostic value for disease 
manifestation is limited.
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